Tango Therapeutics, Inc.
TNGX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $42 | $37 | $25 | $37 |
| % Growth | 15.2% | 46.9% | -32.9% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $42 | $37 | $25 | $37 |
| % Margin | 100% | 100% | 100% | 100% |
| R&D Expenses | $144 | $115 | $106 | $78 |
| G&A Expenses | $44 | $36 | $30 | $18 |
| SG&A Expenses | $44 | $36 | $30 | $18 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $188 | $151 | $136 | $95 |
| Operating Income | -$146 | -$114 | -$111 | -$58 |
| % Margin | -346.1% | -312.6% | -446.8% | -157.1% |
| Other Income/Exp. Net | $16 | $13 | $3 | $0 |
| Pre-Tax Income | -$130 | -$102 | -$108 | -$58 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$130 | -$102 | -$108 | -$58 |
| % Margin | -309.7% | -278.5% | -435.1% | -157.2% |
| EPS | -1.19 | -1.08 | -1.23 | -0.94 |
| % Growth | -10.2% | 12.2% | -30.9% | – |
| EPS Diluted | -1.19 | -1.08 | -1.23 | -0.94 |
| Weighted Avg Shares Out | 109 | 95 | 88 | 62 |
| Weighted Avg Shares Out Dil | 109 | 95 | 88 | 62 |
| Supplemental Information | – | – | – | – |
| Interest Income | $8 | $7 | $1 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $2 | $2 | $2 | $1 |
| EBITDA | -$143 | -$112 | -$109 | -$57 |
| % Margin | -340.1% | -306% | -440.3% | -154.7% |